A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.

Summary

This is a multicenter, active-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 4-week treatment with Stillen tab. in patients with acute or chronic gastritis. Subject will receive Stillen tab or Mucosta tab., three times a day for four weeks.

Conditions

• Acute Gastritis
• Chronic Gastritis

Interventions

DRUG

Stillen Tab.

DRUG

Mucosta Tab.

Sponsors & Collaborators

• Dong-A ST Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Yong Chan Lee, M.D., Ph.D. · Yonsei University, Severance Hospital of Korea

• Jin Il Kim, M.D., Ph.D. · The Catholic University, Yeouido St. Mary's Hospital of Korea

• Kwang Ro Joo, M.D., Ph.D. · Kyung Hee University Gangdong Hospital of Korea

• Dong Il Park, M.D., Ph.D. · Kangbuk Samsung Hospital of Korea

• In Kyung Sung, M.D.,Ph.D. · Konkuk University Hospital of Korea

• Kyu Chan Huh, M.D., Ph.D. · Konyang University Hospital of Korea

• Jung Il Suh, M.D., Ph.D. · Dongguk University Gyeongju Hospital of Korea

• Su Jin Hong, M.D., Ph.D. · Soon Chun Hyang University Bucheon Hospital of Korea

• Jin Heung Kim, M.D., Ph.D. · Ajou University Hospital of Korea

• Dae Hwan Kang, M.D., Ph.D. · Pusan National University Yangsan Hospital of Korea

• Tae Joo Jeon, M.D., Ph.D. · Inje University Sanggye Paik Hospital of Korea

• Tea Oh Kim, M.D., Ph.D. · Inje University Haeundae Paik Hospital of Korea

• Hyun Yong Jeong, M.D., Ph.D. · Chungnam National Unviersity Hospital of Korea

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-10-31

Primary Completion

2013-10-31

Completion

2013-10-31

Countries

• South Korea

Study Locations